Skip to main content
Stem Cell Research & Therapy logoLink to Stem Cell Research & Therapy
. 2021 Sep 6;12:493. doi: 10.1186/s13287-021-02566-5

Correction to: CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells

Bing-zhou Xue 1,#, Wei Xiang 1,#, Qing Zhang 1,2, Hao-fei Wang 1, Yu-jie Zhou 1, Han Tian 1, Ahmed Abdelmaksou 1,3, Jian Xue 4, Min-xuan Sun 5, Dong-ye Yi 1, Nan-xiang Xiong 1, Xiao-bing Jiang 1, Hong-yang Zhao 1, Peng Fu 1,
PMCID: PMC8420013  PMID: 34488861

Correction to: Stem Cell Research & Therapy (2021) 12:394 https://doi.org/10.1186/s13287-021-02458-8

The original article [1] contained an error in Fig. 3B which was given wrong marking figures of NC.U87(0h) and KD.U87(0h).

Fig. 3.

Fig. 3

FOXS1 overexpression induces TMZ resistance in glioma cells. The proliferation (A), wound-healing (B) and apoptosis assay (C) of glioma cells with different FOXS1 expression under 200 μM TMZ treatment. control, normal control; NC, negative control; KD, knockdown; OE, overexpression (n ≥ 3, *P < 0.05, ***P < 0.001)

The original figures and data of Fig. 3 were checked by the authors and the editors of this article, no more figure or data was changed.

The corrected Fig. 3 is presented ahead.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bing-zhou Xue and Wei Xiang contributed equally to this work

Reference

  • 1.Bing-zhou X, et al. CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells. Stem Cell Res Ther. 2021;12:394. doi: 10.1186/s13287-021-02458-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Stem Cell Research & Therapy are provided here courtesy of BMC

RESOURCES